EGFR Non-Small Cell Lung Cancer Market Report Infographic Image

Published : February 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

EGFR Non-Small Cell Lung Cancer Market Report 2026

Name: EGFR Non-Small Cell Lung Cancer Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug Type (Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, Late Phase), By Mutation Type (Exon 19 Deletions, Exon 21 L858R Substitution Mutations, Exon 20 Insertion Mutations, Other Mutation Types), By Treatment Type (Monotherapy, Combination Therapy), By Route of Administration (Oral, Intravenous), By End User (Hospitals, Specialty Oncology Centers, Cancer Research Institutes, Academic Institutes, Other End Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

EGFR Non-Small Cell Lung Cancer Market Overview

• EGFR Non-Small Cell Lung Cancer market size has reached to $9.34 billion in 2025

• Expected to grow to $13.74 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%

• Growth Driver: Rising Adoption Of Personalized Medicine Driving The Growth Of The Market Due To Targeted Therapy And Improved Patient Outcomes

• Market Trend: Advancements In EGFR-Targeted Therapies Using Antibody-Drug Conjugates For NSCLC

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under EGFR Non-Small Cell Lung Cancer Market?

Epidermal growth factor receptor (EGFR) non-small cell lung cancer refers to a subtype of non-small cell lung cancer characterized by mutations or alterations in the epidermal growth factor receptor gene, which plays a critical role in cell growth and division. These genetic changes lead to uncontrolled tumor growth and cancer progression in lung tissue. Epidermal growth factor receptor non-small cell lung cancer is commonly treated using targeted therapies designed to inhibit abnormal receptor signaling and slow disease advancement.

The main drug types of epidermal growth factor receptor (EGFR) non-small cell lung cancer include tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and late phase drugs. Tyrosine kinase inhibitors (TKIs) refer to targeted therapies that block the enzymatic activity of the EGFR protein, preventing cancer cell proliferation and tumor growth. These drugs are used for mutation types including exon 19 deletions, exon 21 L858R substitution mutations, exon 20 insertion mutations, and other mutation types. They are available in treatment types such as monotherapy and combination therapy, and administered via oral or intravenous routes. They are used by end users including hospitals, specialty oncology centers, cancer research institutes, academic institutes, and other end users.

EGFR Non-Small Cell Lung Cancer Market Report bar graph

What Is The EGFR Non-Small Cell Lung Cancer Market Size and Share 2026?

The egfr non-small cell lung cancer market size has grown strongly in recent years. It will grow from $9.34 billion in 2025 to $10.07 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing prevalence of non-small cell lung cancer, advancements in molecular diagnostics, rising awareness of egfr mutation testing, expansion of oncology specialty centers, increased availability of targeted therapies.

What Is The EGFR Non-Small Cell Lung Cancer Market Growth Forecast?

The egfr non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $13.74 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing pipeline of next-generation egfr inhibitors, rising adoption of precision oncology approaches, expansion of biomarker-driven treatment models, growing integration of real-world evidence in oncology care, increasing focus on patient-centric cancer management. Major trends in the forecast period include increasing adoption of targeted egfr therapies, rising use of companion diagnostic testing, growing focus on personalized treatment pathways, expansion of combination therapy approaches, enhanced integration of multidisciplinary cancer care.

Book your 30 minutes free consultation with our research experts

Global EGFR Non-Small Cell Lung Cancer Market Segmentation

1) By Drug Type: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Late Phase

2) By Mutation Type: Exon 19 Deletions; Exon 21 L858R Substitution Mutations; Exon 20 Insertion Mutations; Other Mutation Types

3) By Treatment Type: Monotherapy; Combination Therapy

4) By Route of Administration: Oral; Intravenous

5) By End User: Hospitals; Specialty Oncology Centers; Cancer Research Institutes; Academic Institutes; Other End Users

Subsegments:

1) By Tyrosine Kinase Inhibitors: First Generation Tyrosine Kinase Inhibitors; Second Generation Tyrosine Kinase Inhibitors; Third Generation Tyrosine Kinase Inhibitors

2) By Monoclonal Antibodies: Anti Epidermal Growth Factor Receptor Monoclonal Antibodies; Dual Target Monoclonal Antibodies; Antibody Drug Conjugates

3) By Late Phase: Patritumab Deruxtecan; Other Late Phase Pipeline Therapies

What Is The Driver Of The EGFR Non-Small Cell Lung Cancer Market?

The increasing focus on personalized medicine approaches is expected to propel the growth of the epidermal growth factor receptor (EGFR) non-small cell lung cancer market going forward. Personalized medicine is a medical approach that tailors prevention, diagnosis, and treatment strategies to an individual’s genetic, environmental, and lifestyle factors. Personalized medicine approaches are rising due to the growing accessibility of genetic and molecular profiling, which enables precise identification of disease-specific targets and allows treatments to be tailored for improved patient outcomes. Personalized medicine approaches support EGFR non-small cell lung cancer by detecting specific EGFR mutations in patients, allowing doctors to prescribe targeted therapies that maximize effectiveness while minimizing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA authorized 16 new personalized therapies for patients with rare diseases in 2023, a significant increase from the six approvals recorded in 2022. Therefore, the increasing focus on personalized medicine approaches is driving the growth of the epidermal growth factor receptor (EGFR) non-small cell lung cancer market.

Key Players In The Global EGFR Non-Small Cell Lung Cancer Market

Major companies operating in the egfr non-small cell lung cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca Plc, Bayer AG, Eli Lilly and Company, Takeda Pharmaceuticals Company Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd., Betta Pharmaceuticals Co. Ltd., ShanghAI Allist Pharmaceuticals Co. Ltd., Oric Pharmaceuticals Inc., Black Diamond Therapeutics Inc., G1 Therapeutics Inc., Dizal Pharmaceutical, ArriVent BioPharma Inc., and Cullinan Therapeutics Inc.

Global EGFR Non-Small Cell Lung Cancer Market Trends and Insights

Major companies operating in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market are focusing on developing innovative products, such as antibody drug conjugates, to improve treatment efficacy while reducing systemic side effects compared to conventional chemotherapy. An antibody-drug conjugate (ADC) is a therapy that links a cancer-targeting antibody to a powerful drug, allowing the medication to be delivered directly to tumor cells while sparing normal cells. For instance, in June 2025, AstraZeneca Plc, a UK-based biopharmaceutical company, announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received approval in the U.S. for treating adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have previously undergone EGFR-targeted therapy and platinum-based chemotherapy. This indication was granted accelerated approval based on the observed objective response rate (ORR) and duration of response (DoR), with continued approval dependent on confirmation of clinical benefit in a subsequent trial. The U.S. FDA granted the approval following Priority Review and Breakthrough Therapy Designation. The decision was supported by a subgroup analysis from the TROPION-Lung05 Phase II trial and additional evidence from the TROPION-Lung01 Phase III trial.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The EGFR Non-Small Cell Lung Cancer Market?

In October 2023, Daiichi Sankyo, a Japan-based company specializing in EGFR non-small cell lung cancer (NSCLC) treatment, collaborated with Merck Co. Inc. to create and bring to market three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates. As a result of the collaboration, the companies will jointly develop and potentially commercialize atritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd) worldwide, with Daiichi Sankyo retaining exclusive rights in Japan and sole responsibility for manufacturing and supply. Notably, patritumab deruxtecan has received breakthrough therapy designation from the U.S. FDA for treating patients with EGFR mutated locally advanced or metastatic NSCLC whose disease progressed after third-generation tyrosine kinase inhibitors and platinum-based therapies. Merck Co. Inc. is a US-based pharmaceutical company.

Regional Insights

North America was the largest region in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the EGFR Non-Small Cell Lung Cancer Market?

The epidermal growth factor receptor (EGFR) non-small cell lung cancer market consists of revenues earned by entities by providing services such as pathological and diagnostic evaluation, personalized treatment planning, immunotherapy support services, radiation oncology services, patient consultation and clinical management, adverse event management, and supportive and palliative care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The epidermal growth factor receptor (EGFR) non-small cell lung cancer market also includes sales of companion diagnostic kits, biomarker testing assays, supportive care drugs, and combination chemotherapy regimens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the EGFR Non-Small Cell Lung Cancer Market Report 2026?

The egfr non-small cell lung cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the egfr non-small cell lung cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

EGFR Non-Small Cell Lung Cancer Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$10.07 billion
Revenue Forecast In 2035	$13.74 billion
Growth Rate	CAGR of 7.8% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Drug Type, Mutation Type, Treatment Type, Route of Administration, End User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca Plc, Bayer AG, Eli Lilly and Company, Takeda Pharmaceuticals Company Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd., Betta Pharmaceuticals Co. Ltd., ShanghAI Allist Pharmaceuticals Co. Ltd., Oric Pharmaceuticals Inc., Black Diamond Therapeutics Inc., G1 Therapeutics Inc., Dizal Pharmaceutical, ArriVent BioPharma Inc., and Cullinan Therapeutics Inc.
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. EGFR Non-Small Cell Lung Cancer Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global EGFR Non-Small Cell Lung Cancer Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. EGFR Non-Small Cell Lung Cancer Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global EGFR Non-Small Cell Lung Cancer Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Artificial Intelligence & Autonomous Intelligence

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Increasing Adoption Of Targeted Egfr Therapies

4.2.2 Rising Use Of Companion Diagnostic Testing

4.2.3 Growing Focus On Personalized Treatment Pathways

4.2.4 Expansion Of Combination Therapy Approaches

4.2.5 Enhanced Integration Of Multidisciplinary Cancer Care

5. EGFR Non-Small Cell Lung Cancer Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Oncology Centers

5.3 Cancer Research Institutes

5.4 Academic Medical Centers

5.5 Oncology Clinics

6. EGFR Non-Small Cell Lung Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global EGFR Non-Small Cell Lung Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global EGFR Non-Small Cell Lung Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global EGFR Non-Small Cell Lung Cancer Market Size, Comparisons And Growth Rate Analysis

7.3. Global EGFR Non-Small Cell Lung Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global EGFR Non-Small Cell Lung Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global EGFR Non-Small Cell Lung Cancer Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. EGFR Non-Small Cell Lung Cancer Market Segmentation

9.1. Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, Late Phase

9.2. Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Exon 19 Deletions, Exon 21 L858R Substitution Mutations, Exon 20 Insertion Mutations, Other Mutation Types

9.3. Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Monotherapy, Combination Therapy

9.4. Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Intravenous

9.5. Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Specialty Oncology Centers, Cancer Research Institutes, Academic Institutes, Other End Users

9.6. Global EGFR Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Tyrosine Kinase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

First Generation Tyrosine Kinase Inhibitors, Second Generation Tyrosine Kinase Inhibitors, Third Generation Tyrosine Kinase Inhibitors

9.7. Global EGFR Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Anti Epidermal Growth Factor Receptor Monoclonal Antibodies, Dual Target Monoclonal Antibodies, Antibody Drug Conjugates

9.8. Global EGFR Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Late Phase, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Patritumab Deruxtecan, Other Late Phase Pipeline Therapies

10. EGFR Non-Small Cell Lung Cancer Market Regional And Country Analysis

10.1. Global EGFR Non-Small Cell Lung Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global EGFR Non-Small Cell Lung Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific EGFR Non-Small Cell Lung Cancer Market

11.1. Asia-Pacific EGFR Non-Small Cell Lung Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China EGFR Non-Small Cell Lung Cancer Market

12.1. China EGFR Non-Small Cell Lung Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India EGFR Non-Small Cell Lung Cancer Market

13.1. India EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan EGFR Non-Small Cell Lung Cancer Market

14.1. Japan EGFR Non-Small Cell Lung Cancer Market Overview

14.2. Japan EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia EGFR Non-Small Cell Lung Cancer Market

15.1. Australia EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia EGFR Non-Small Cell Lung Cancer Market

16.1. Indonesia EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea EGFR Non-Small Cell Lung Cancer Market

17.1. South Korea EGFR Non-Small Cell Lung Cancer Market Overview

17.2. South Korea EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan EGFR Non-Small Cell Lung Cancer Market

18.1. Taiwan EGFR Non-Small Cell Lung Cancer Market Overview

18.2. Taiwan EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia EGFR Non-Small Cell Lung Cancer Market

19.1. South East Asia EGFR Non-Small Cell Lung Cancer Market Overview

19.2. South East Asia EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe EGFR Non-Small Cell Lung Cancer Market

20.1. Western Europe EGFR Non-Small Cell Lung Cancer Market Overview

20.2. Western Europe EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK EGFR Non-Small Cell Lung Cancer Market

21.1. UK EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany EGFR Non-Small Cell Lung Cancer Market

22.1. Germany EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France EGFR Non-Small Cell Lung Cancer Market

23.1. France EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy EGFR Non-Small Cell Lung Cancer Market

24.1. Italy EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain EGFR Non-Small Cell Lung Cancer Market

25.1. Spain EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe EGFR Non-Small Cell Lung Cancer Market

26.1. Eastern Europe EGFR Non-Small Cell Lung Cancer Market Overview

26.2. Eastern Europe EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia EGFR Non-Small Cell Lung Cancer Market

27.1. Russia EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America EGFR Non-Small Cell Lung Cancer Market

28.1. North America EGFR Non-Small Cell Lung Cancer Market Overview

28.2. North America EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA EGFR Non-Small Cell Lung Cancer Market

29.1. USA EGFR Non-Small Cell Lung Cancer Market Overview

29.2. USA EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada EGFR Non-Small Cell Lung Cancer Market

30.1. Canada EGFR Non-Small Cell Lung Cancer Market Overview

30.2. Canada EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America EGFR Non-Small Cell Lung Cancer Market

31.1. South America EGFR Non-Small Cell Lung Cancer Market Overview

31.2. South America EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil EGFR Non-Small Cell Lung Cancer Market

32.1. Brazil EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East EGFR Non-Small Cell Lung Cancer Market

33.1. Middle East EGFR Non-Small Cell Lung Cancer Market Overview

33.2. Middle East EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa EGFR Non-Small Cell Lung Cancer Market

34.1. Africa EGFR Non-Small Cell Lung Cancer Market Overview

34.2. Africa EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Mutation Type, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. EGFR Non-Small Cell Lung Cancer Market Regulatory and Investment Landscape

36. EGFR Non-Small Cell Lung Cancer Market Competitive Landscape And Company Profiles

36.1. EGFR Non-Small Cell Lung Cancer Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. EGFR Non-Small Cell Lung Cancer Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. EGFR Non-Small Cell Lung Cancer Market Company Profiles

36.3.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. EGFR Non-Small Cell Lung Cancer Market Other Major And Innovative Companies

Eli Lilly and Company, Takeda Pharmaceuticals Company Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd., Betta Pharmaceuticals Co. Ltd., Shanghai Allist Pharmaceuticals Co. Ltd., Oric Pharmaceuticals Inc., Black Diamond Therapeutics Inc., G1 Therapeutics Inc., Dizal Pharmaceutical, ArriVent BioPharma Inc., Cullinan Therapeutics Inc.

38. Global EGFR Non-Small Cell Lung Cancer Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The EGFR Non-Small Cell Lung Cancer Market

41. EGFR Non-Small Cell Lung Cancer Market High Potential Countries, Segments and Strategies

41.1 EGFR Non-Small Cell Lung Cancer Market In 2030 - Countries Offering Most New Opportunities

41.2 EGFR Non-Small Cell Lung Cancer Market In 2030 - Segments Offering Most New Opportunities

41.3 EGFR Non-Small Cell Lung Cancer Market In 2030 - Growth Strategies

41.3.1 Market Trend Based Strategies

41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations

42.2. Currencies

42.3. Historic And Forecast Inflation Rates

42.4. Research Inquiries

42.5. The Business Research Company

42.6. Copyright And Disclaimer

List Of Tables

Table 1: Global EGFR Non-Small Cell Lung Cancer Market, Overview Of Key Products - Product Examples

Table 2: Global EGFR Non-Small Cell Lung Cancer Market Attractiveness, Factor-Wise Evaluation

Table 3: Global EGFR Non-Small Cell Lung Cancer Market, Supply Chain Analysis

Table 4: Global EGFR Non-Small Cell Lung Cancer Market, Major Raw Material Providers

Table 5: Global EGFR Non-Small Cell Lung Cancer Market, Major Resource Providers

Table 6: Global EGFR Non-Small Cell Lung Cancer Market, Major Manufacturers (Suppliers)

Table 7: Global EGFR Non-Small Cell Lung Cancer Market, Major Distributors And Channel Partners

Table 8: Global EGFR Non-Small Cell Lung Cancer Market, Key Technologies & Future Trends

Table 9: Global EGFR Non-Small Cell Lung Cancer Market, Major Trends

Table 10: Global EGFR Non-Small Cell Lung Cancer Market, Major End Users

Table 11: Global EGFR Non-Small Cell Lung Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global EGFR Non-Small Cell Lung Cancer Historic Market Growth, 2020-2025, $ Billion

Table 13: Global EGFR Non-Small Cell Lung Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global EGFR Non-Small Cell Lung Cancer Market - TAM, US$ Billion, 2025

Table 15: Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global EGFR Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Tyrosine Kinase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global EGFR Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global EGFR Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Late Phase, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global EGFR Non-Small Cell Lung Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global EGFR Non-Small Cell Lung Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Global EGFR Non-Small Cell Lung Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 98: Global EGFR Non-Small Cell Lung Cancer Market - Company Scoring Matrix

Table 99: Upcoming Startups

Table 100: Johnson & Johnson Services Inc. Financial Performance

Table 101: F. Hoffmann-La Roche Ltd Financial Performance

Table 102: Pfizer Inc. Financial Performance

Table 103: AstraZeneca Plc Financial Performance

Table 104: Bayer AG Financial Performance

Table 105: Global EGFR Non-Small Cell Lung Cancer Market, Competitive Benchmarking (In USD Billions)

Table 106: Global EGFR Non-Small Cell Lung Cancer Market, Competitive Dashboard

Table 107: Global EGFR Non-Small Cell Lung Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 108: Global, EGFR Non-Small Cell Lung Cancer Market Size Gain ($ Billion), Segmentation By Drug Type, 2025 – 2030

Table 109: Global, EGFR Non-Small Cell Lung Cancer Market Size Gain ($ Billion), Segmentation By Mutation Type, 2025 – 2030

Table 110: Global, EGFR Non-Small Cell Lung Cancer Market Size Gain ($ Billion), Segmentation By Treatment Type, 2025 – 2030

List Of Figures

Figure 1: Global EGFR Non-Small Cell Lung Cancer Market, Overview Of Key Products - Product Examples

Figure 2: Global EGFR Non-Small Cell Lung Cancer Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global EGFR Non-Small Cell Lung Cancer Market, Supply Chain Analysis

Figure 4: Global EGFR Non-Small Cell Lung Cancer Market, Major Raw Material Providers

Figure 5: Global EGFR Non-Small Cell Lung Cancer Market, Major Resource Providers

Figure 6: Global EGFR Non-Small Cell Lung Cancer Market, Major Manufacturers (Suppliers)

Figure 7: Global EGFR Non-Small Cell Lung Cancer Market, Major Distributors And Channel Partners

Figure 8: Global EGFR Non-Small Cell Lung Cancer Market, Key Technologies & Future Trends

Figure 9: Global EGFR Non-Small Cell Lung Cancer Market, Major Trends

Figure 10: Global EGFR Non-Small Cell Lung Cancer Market, Major End Users

Figure 11: Global EGFR Non-Small Cell Lung Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global EGFR Non-Small Cell Lung Cancer Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global EGFR Non-Small Cell Lung Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global EGFR Non-Small Cell Lung Cancer Market - TAM, US$ Billion, 2025

Figure 15: Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global EGFR Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global EGFR Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Tyrosine Kinase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global EGFR Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global EGFR Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Late Phase, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global EGFR Non-Small Cell Lung Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global EGFR Non-Small Cell Lung Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Mutation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, EGFR Non-Small Cell Lung Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Global EGFR Non-Small Cell Lung Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 98: Global EGFR Non-Small Cell Lung Cancer Market - Company Scoring Matrix

Figure 99: Upcoming Startups

Figure 100: Johnson & Johnson Services Inc. Financial Performance

Figure 101: F. Hoffmann-La Roche Ltd Financial Performance

Figure 102: Pfizer Inc. Financial Performance

Figure 103: AstraZeneca Plc Financial Performance

Figure 104: Bayer AG Financial Performance

Figure 105: Global EGFR Non-Small Cell Lung Cancer Market, Competitive Benchmarking (In USD Billions)

Figure 106: Global EGFR Non-Small Cell Lung Cancer Market, Competitive Dashboard

Figure 107: Global EGFR Non-Small Cell Lung Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 108: Global, EGFR Non-Small Cell Lung Cancer Market Size Gain ($ Billion), Segmentation By Drug Type, 2025 – 2030

Figure 109: Global, EGFR Non-Small Cell Lung Cancer Market Size Gain ($ Billion), Segmentation By Mutation Type, 2025 – 2030

Figure 110: Global, EGFR Non-Small Cell Lung Cancer Market Size Gain ($ Billion), Segmentation By Treatment Type, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Non-Small Cell Lung Cancer NSCLC Market 2025 - By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types), By Therapy (Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Other The...

Lung Cancer Drugs Market Report 2026 - Global Outlook – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cance...

Advanced Renal Cell Carcinoma Treatment Market Report 2026 - Global Outlook – By Treatment (Biologics, Radiation Therapy), By Route Of Administration (Parental, Oral, Other Routes Of Administration), By End User (Hospita...

Small Cell Lung Cancer Therapeutics Market Report 2026 - Global Outlook – By Drug Type (Atezolizumab, Topotecan, Lurbinectedin, Durvalumab, Methotrexate, Pembrolizumab), By Treatment Type (Chemotherapy, Targeted Therapy,...

Non-Small Cell Lung Cancer (NSCLC) Market Report 2026 - Global Outlook – By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types), By Therapy (Radiotherapy, Laser Therapy, Photodynamic Therapy...

Frequently Asked Questions

How big is the EGFR Non-Small Cell Lung Cancer Market?

The EGFR Non-Small Cell Lung Cancer market was valued at $9.34 billion in 2025, increased to $10.07 billion in 2026, and is projected to reach $13.74 billion by 2030.

What is the EGFR Non-Small Cell Lung Cancer market growth?

The global EGFR Non-Small Cell Lung Cancer market is expected to grow at a CAGR of 8.1% from 2026 to 2035 to reach $13.74 billion by 2035.

Who are the key players in EGFR Non-Small Cell Lung Cancer market?

Some Key Players in the EGFR Non-Small Cell Lung Cancer market Include, Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca Plc, Bayer AG, Eli Lilly and Company, Takeda Pharmaceuticals Company Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd., Betta Pharmaceuticals Co. Ltd., ShanghAI Allist Pharmaceuticals Co. Ltd., Oric Pharmaceuticals Inc., Black Diamond Therapeutics Inc., G1 Therapeutics Inc., Dizal Pharmaceutical, ArriVent BioPharma Inc., and Cullinan Therapeutics Inc. .

What is the anticipated growth trend for the EGFR Non-Small Cell Lung Cancer market?

Major trend in this market includes: Advancements In EGFR-Targeted Therapies Using Antibody-Drug Conjugates For NSCLC. For further insights on this market. request a sample here

Which region has the most growth potential in the EGFR Non-Small Cell Lung Cancer market?

North America was the largest region in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egfr non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.